A study found that litifilimab, a humanized monoclonal antibody that binds blood dendritic cell antigen 2, may be effective for the treatment of patients with active cutaneous lupus erythematosus. The treatment successfully reduced skin disease activity in patients at 16 weeks compared with placebo.
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…
NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot…
NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the…
Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes…
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…
In its second indication in the EU, ixekizumab has been approved by the European Commission to treat adults with active psoriatic arthritis…
NEW YORK (Reuters Health)—Using tumor necrosis factor alpha (TNF-alpha) inhibitors for atypical dermatoses may unmask, or perhaps even worsen, cutaneous lymphoma, according to new research. “Our findings suggest that careful skin examination might be required in all patients prescribed anti-TNF-alpha agents, especially those with atypical presentations of benign skin conditions,” says Dr. Joan Guitart of…
Preliminary results from an ongoing study show that bimekizumab improves joint and skin symptoms in patients with psoriatic arthritis…